Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 2
1997 4
1998 8
1999 9
2000 7
2001 8
2002 2
2003 4
2004 3
2005 7
2006 1
2007 1
2008 6
2009 3
2010 5
2011 4
2012 6
2013 2
2014 5
2015 11
2016 10
2017 8
2018 3
2019 4
2020 3
2021 4
2022 5
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: tetzlaff k. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: tetzlaff k. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H, Anadkat MJ, Rajeswari S, Hua H, Vulcu SD, Hall D, Tetzlaff K, Thoma C, Lebwohl MG; Effisayil 1 Trial Investigators. Bachelez H, et al. Among authors: tetzlaff k. N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563. N Engl J Med. 2021. PMID: 34936739 Clinical Trial.
Challenges for Clinical Drug Development in Pulmonary Fibrosis.
White ES, Thomas M, Stowasser S, Tetzlaff K. White ES, et al. Among authors: tetzlaff k. Front Pharmacol. 2022 Jan 31;13:823085. doi: 10.3389/fphar.2022.823085. eCollection 2022. Front Pharmacol. 2022. PMID: 35173620 Free PMC article. Review.
The natural history of progressive fibrosing interstitial lung diseases.
Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. Brown KK, et al. Among authors: tetzlaff k. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32217654 Free PMC article.
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
Choon SE, Lebwohl MG, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H, Rajeswari S, Deng H, Tetzlaff K, Thoma C, Bachelez H. Choon SE, et al. Among authors: tetzlaff k. BMJ Open. 2021 Mar 30;11(3):e043666. doi: 10.1136/bmjopen-2020-043666. BMJ Open. 2021. PMID: 33785490 Free PMC article.
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR; INBUILD trial investigators. Maher TM, et al. Among authors: tetzlaff k. Eur Respir J. 2022 Feb 3;59(2):2004587. doi: 10.1183/13993003.04587-2020. Print 2022 Feb. Eur Respir J. 2022. PMID: 34210788 Free PMC article.
Return to diving after COVID-19.
Tetzlaff K. Tetzlaff K. Eur J Prev Cardiol. 2022 Jul 20;29(9):e290. doi: 10.1093/eurjpc/zwac066. Eur J Prev Cardiol. 2022. PMID: 35403202 Free PMC article. No abstract available.
Going to Extremes of Lung Physiology-Deep Breath-Hold Diving.
Tetzlaff K, Lemaitre F, Burgstahler C, Luetkens JA, Eichhorn L. Tetzlaff K, et al. Front Physiol. 2021 Jul 9;12:710429. doi: 10.3389/fphys.2021.710429. eCollection 2021. Front Physiol. 2021. PMID: 34305657 Free PMC article. Review.
Effects of Breath-Hold Deep Diving on the Pulmonary System.
Schipke JD, Lemaitre F, Cleveland S, Tetzlaff K. Schipke JD, et al. Among authors: tetzlaff k. Respiration. 2019;97(5):476-483. doi: 10.1159/000495757. Epub 2019 Feb 15. Respiration. 2019. PMID: 30783070 Review.
123 results